TAURIGA SCIENCES INC - TAUG STOCK NEWS

Tauriga Sciences, Inc. (OTCQB: TAUG) announced that CEO Seth M. Shaw purchased 1,500,000 shares of the company's stock between May 5-9, 2022. This insider transaction demonstrates Shaw's confidence in the company's future. Tauriga is focused on developing life sciences and pharmaceutical products, including its Tauri-Gum™ line, which features various CBD and CBG infused flavors. The company is also pursuing pharmaceutical-grade products for chemotherapy-related nausea regulation, backed by a U.S. Non-Provisional Patent Application.

Tauriga Sciences, Inc. (OTCQB: TAUG) has achieved a milestone by processing its 10,000th E-Commerce order, setting a new quarterly record for individual transactions. This success is attributed to a growing number of repeat customers, an expanded product range, effective influencer marketing, and improved conversion rates on their website. Additionally, the company is optimistic as the U.S. House of Representatives has scheduled a vote on the Federal Marijuana Legalization Bill for the week of March 28 to April 1, 2022.

Tauriga Sciences, Inc. (TAUG), a diversified Retail Life Sciences and Pharmaceutical Development Company based in New York, has been invited to the Kroger "Merchandising Planogram and Sales Planning" event on March 23, 2022. This participation highlights the company's strategy to strengthen relationships with major retailers. Additionally, Tauriga is optimistic about forthcoming Federal Cannabis Legislation and has reported over 1,150 E-Commerce orders in the current quarter, totaling 9,690 since 2019.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced a significant milestone, receiving its 9,000th E-Commerce order, showcasing the effectiveness of its aggressive marketing strategy. The company continues to advance its pharmaceutical development efforts, particularly focusing on Tauri-Gum™, a product designed for nausea regulation in chemotherapy patients. The company holds a U.S. Non-Provisional Patent for its CBD compositions. Tauriga operates two E-Commerce fulfillment centers, enhancing its distribution capabilities.

Tauriga Sciences, Inc. (TAUG) reported impressive quarterly results, with E-Commerce sales exceeding $110,000, marking a 75% sequential growth, while Amazon sales grew 60% Q-to-Q. This signifies a strong trend in their E-Commerce segment, which is the highest gross margin source for the company. The new E-Commerce website was launched on January 1, 2022, enhancing its online presence. The company focuses on CBD and CBG products, with a strategic initiative in pharmaceutical development for chemotherapy-related nausea.

Tauriga Sciences (OTCQB: TAUG) has received a Product Endorsement Approval Notice from the State of Alaska for its Tauri-Gum™ product line. Issued on December 20, 2021, by the Alaska Division of Agriculture, this endorsement acknowledges the company's commitment to compliance in the industrial hemp program. Tauriga specializes in manufacturing CBD and CBG edibles, with the Tauri-Gum™ line featuring various infused flavors such as mint, blood orange, and caffeine. This endorsement may enhance the product's marketability and establish credibility in the industry.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced record quarterly net revenue for Q3 of fiscal year 2022, driven by the growth of its high-margin E-Commerce segment. This marks the second consecutive quarter of record revenue for the company. Tauriga is actively pursuing several promising catalysts and remains optimistic about its business prospects. The company specializes in CBD and CBG edibles, including its flagship product, Tauri-Gum™, and operates in pharmaceutical development for nausea regulation in chemotherapy patients.

Tauriga Sciences, Inc. (TAUG) announced the submission of its Clinical Study Protocol titled The Effect of CBD Gum on Nausea and Vomiting During Pregnancy to the Institutional Review Board (IRB) for review. The study aims to evaluate the impact of different cannabidiol doses on nausea severity in pregnant women experiencing Hyperemesis Gravidarum. The IRB acknowledged receipt of the protocol, which involves Tauriga's proprietary CBD-infused chewing gum designed for sublingual absorption. The company is also working on a pharmaceutical-grade version for nausea regulation during chemotherapy.

Tauriga Sciences, Inc. (OTCQB: TAUG) has renewed its status as an Affiliate Vendor to the National Association of College Stores (NACS) for 2022. This partnership provides access to a $10 billion collegiate retail market, which the company believes offers lucrative business opportunities. Additionally, Tauriga will have a corporate Exhibitor Booth at the NACS Campus Market Expo 2022 from February 26 to March 2 in Louisville, Kentucky. The company specializes in CBD and CBG edibles, including Tauri-Gum™ products, and is engaged in pharmaceutical development targeting chemotherapy-related nausea.